Work

Novel formulations for Amphotericin B Delivery

Year: 2017
Type: article
Abstract: SUMMARY \n \nNOVEL FORMULATIONS FOR AMPHOTERICIN B DELIVERY \nINTRODUCTION \nAmphotericin B (AmB), a macrolide antibiotic with broad spectra of action, has been widely used in the treatment of systemic fungal infections since more than 40 years. Even though several new antifungal drugs have been developed, AmB remains the drug of choice in the treatment of severe systemic fungal diseases and in the treatment of visceral leishmaniasis when the parasite develops resistance to antimonial compounds. \nThe poor AmB solubility is the main drawback for the development of pharmaceutical formulations. So far, many attempts have been made to develop AmB formulations with enhanced therapeutic profiles, including solid-lipid nanoparticles, polymeric nanoparticles, liposomes, micelles and polymer bioconjugates. \nEven though the amphotericin B associated nephrotoxicity is the main drawback for the use of this molecule in clinic, the fact that this antibiotic is only available for intravenous administration also limits its prescription. The development of AmB oral, intravenous and/or topical formulations with decreased toxicity will allow not only for the treatment of systemic fungal infections but also for the treatment of topical mixed-infections resistant to conventional treatments. These formulations will improve patient compliance and reduce the sanitary cost of the treatment. \nOBJECTIVE \nTaking into account the rising importance and clinical repercussion of the mold infections in humans and animals, the development of new formulations that reinforce the current therapeutic arsenal is needed. \nThe wide spectra of action of amphotericin B together with its low appearance of resistance, makes this drug a suitable candidate for the treatment of different types of mycosis. Thus, the main objective of the present thesis will be focused on the development of new amphotericin B (AmB) formulations for the treatment of systemic and topical mycosis with reduced side effects. \nTwo AmB formulations will be developed. The first part of this project will be focused on the development of a new AmB topical formulation; a nail lacquer formulation for the treatment of mixed onychomycosis resistant to conventional treatments. \nThe second part of the thesis will be performed in collaboration with the University Degli Studi di Padova and it will be focused on the development and optimization of an AmB pegylated formulation for the treatment of systemic fungal infections by oral and intravenous administration. The AmB interactions with cholesterol-type molecules are known to favor the drug solubility. Thus, the conjugation of cholesterol-type molecules with different PEGs will allow for the encapsulation and solubilization of AmB. To achieve this general purpose some specific objectives are proposed which included the synthesis of different AmB pegylated complexes; the solubility studies in different conditions; the complexes characterization by DLS, HPLC, DSC, RX, FTIR, CD, ITC and synchrotron analysis; the ex vivo characterization of these complexes (toxicity by hemolysis and antifungal efficacy against Candida albicans) and finally, the in vivo pharmacokinetic studies after oral and intravenous administration. The pharmacokinetic properties of the new AmB formulation will be determined and compared to the commercialized formulations Ambisome® and Fungizone®. \nRESULTS \nWith regards to the AmB topical formulation, different water permeable and impermeable nail lacquer formulations were prepared. The drying time, viscosity, aspect of the film, extensibility, brightness, AmB incorporation and pH were studied. From all the formulations developed, three of them were selected for further characterization and in vitro studies (F11, F13 and F19). Even though formulations 11, 13 and 19 overcame the AmB low solubility problems, the short-term stability of these formulations (1 month) was still a problem. The strategy used to overcome the short AmB stability was focused on obtaining powders for reconstitution. The freeze drying (for F11 and F13) and spray drying (for F19) generated stable lyophilized and spray dried products easily redispersable. In vitro nail penetration studies on female human nails, demonstrated the higher nail penetration reached with F19 (EF=1.95) compared to F11, F13 and to the control. The in vitro efficacy studies against Candida albicans showed that the most active formulation was F19 (103%). The AmB nail lacquer was active against the dermatophyte and non-dermatophyte infections located on keratinized structures. Treatment (30 days) with F19, administered in alternate days, once daily, cleared up the infections caused by T. mentagrophytes, T. rubrum, A. niger, F.oxysporum and F.solani. After 30 days of treatment no microorganisms were found nor in the culture media neither in the direct examination. \nAs far as the AmB pegylated formulation is concerned, the solubility studies showed that PEG5kDa-cholane can increase more than 105 times the AmB solubility according to a linear [dissolved drug]/ [polymer concentration] correlation. The different capability of PEG5kDa-cholane to solubilize AmB observed was explained by the effect of the dissolution conditions in the formation of monomeric and multimeric soluble species. The high affinity of AmB for PEG5kDa-cholane was observed by isothermal calorimetry (ITC). This technique highlighted the complexity of the PEG5kDa-cholane interaction with AmB, which takes place with different AmB soluble species, namely monomers, dimers, tetramers, and other multimeric nanoaggregates, of which abundance depends on the pH. The three different binding sites calculated by ITC analyses reasonably result from the PEG5kDa-cholane interaction with different AmB species through hydrophobic interactions between the cholane moiety and the heptaene side of the drug molecule to form different supramolecular structures. The lyophilization process produced a fluffy powder with low moisture content and without cake formation which was stable throughout the time. The CD studies showed that, similarly to Fungizone® and heated Fungizone®, AmB/PEG5kDa-cholane micelles did not induce structural alterations of human serum albumin (HSA). The hemolysis studies confirmed that the AmB/PEG5kDa-cholane micelles were less hemolytic than Fungizone®. Even at concentrations in which the Fungizone® caused 100% hemolysis, the new formulation produced not more than 30% hemolysis. The biological in vitro studies showed that the AmB formulated with PEG5kDa-cholane maintains high antimicrobial activity, which is very close to AmB in solution. The oral administration of 5 mg/kg AmB demonstrated that the new formulation developed had the highest half-life of all assayed formulations. \nFinally, The IV administration of 1 mg/kg AmB in Ambisome®, Fungizone® and AmB/PEG5kDa-cholane showed that the new formulation developed had a significantly (P<0.01) lower apparent elimination constant and consequently, a higher half-life compared to the marketed formulations Ambisome® and Fungizone®. \n \nCONCLUSIONS \nThis thesis includes the development of two different types of amphotericin B formulations: one topical formulation for the treatment of nail infections (conclusions 1-3) and one intravenous/oral formulation for the treatment systemic fungal infections. (Conclusions 4-12). \nConclusions: \n1.- A new water-impermeable stable nail lacquer formulation containing amphotericin B has been designed for the treatment of onychomycosis. The polymer (Eudragit L100®) and the amphotericin B solvent used (N-methyl-2-pyrrolidone) showed no compatibility problems. Once applied over a surface, the nail lacquer formed a continuous, homogenous and smooth film resistant to water. \n2.- In vitro nail penetration studies showed that the lacquer was able to penetrate the nail (enhancement factor almost twice than the control). In vitro activity studies demonstrated the efficacy of the nail lacquer against dermatophyte and non-dermatophyte molds as well as yeasts (gender Candida). \n3.- In vivo efficacy studies on keratinized structures of animal origin supported the efficacy of amphotericin B. After 30 days treatment on alternate days, the nail lacquer was able to clear up the infections caused by Trichophyton mentagrophytes, Trichophyton rubrum, Aspergillus niger, Fusarium. oxysporum and Fusarium solani. \n4.- A novel formulation for amphotericin B delivery has been developed by using a micelle forming 5 kDa monomethoxy-polyethylene glycol end functionalized with cholanic acid (PEG5kDa-cholane). This polymer was found to increase 105 times the amphotericin B solubility with a 12:1 AmB/PEG5kDa-cholane molar ratio (2:1 w/w ratio). \n5.- The system AmB/PEG5kDa-cholane forms 30 nm micelles with the hydrophobic cholane moieties localized inside the micelles. Zeta potential analysis showed that at neutral pHs (5.5-7.2) the overall micelle surface is nearly neutral. The PEG5kDa-cholane interacts with amphotericin B according to three binding sites depending on the pH, suggesting that the polymer interaction depends on the amphotericin B ionization and aggregation. \n6.- Once lyophilized, the freeze-dried product could be promptly redispersed to form an homogeneous colloidal dispersion. The dispersion was physicochemically stable. Fourier Transform infrared spectrometry, differential scanning calorimetry and X-ray diffractometry showed that in the lyophilized product, amphotericin B and PEG5kDa-cholane interacts intimately. \n7.- The amphotericin B release from the PEG5kDa-cholane micelles showed a biphasic profile. The best fittings were obtained with the Higuchi and Korsmeyer-Peppas models. \n8.- The toxicity of the new formulation was tested as hemolysis. The new AmB/PEG5kDa-cholane nanoformulation was always less hemolytic than t
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2782549126
FWCI:
Cites: 416
Cited by:
Related to: 10